Drugs / BI 1358894
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT05934942 | Sep 2023 → Feb 2024 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT05155306 | Jan → May 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04899674 | Jun → Sep 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04567316 | Oct 2020 → Jan 2021 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04426851 | Jul → Oct 2020 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04099732 | Oct → Dec 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03904576 | Apr → Aug 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03892616 | Apr → Jul 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03875001 | Mar → Jul 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03843151 | Mar → Jun 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03854578 | Mar → Aug 2019 | major depressive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03754959 | Dec 2018 → Jul 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03210272 | Jul 2017 → Feb 2019 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05103657 | Dec 2021 → Oct 2023 | post-traumatic stress disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT04521478 | Nov 2020 → Jan 2024 | major depressive disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT04566601 | Nov 2020 → Dec 2022 | borderline personality disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT04423757 | Jun 2020 → Apr 2022 | major depressive disorder | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1358894 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05934942 ↗ |
| Action | Inhibit | “BI 1358894, a small-molecule inhibitor of TRPC ion channels, is currently being developed for the treatment of MDD.” PMID 38019355 ↗ Nov 2023 |
| Modality | Small molecule | “BI 1358894, a small-molecule inhibitor of TRPC ion channels, is currently being developed for the treatment of MDD.” PMID 38019355 ↗ Nov 2023 |
| Route | Oral | “oral administration of single rising doses” NCT03210272 ↗ |
| Target | TRPC4 | “TRPC ion channel members 4 and 5 (TRPC4/5)” PMID 38019356 ↗ Nov 2023 |